
Detailing the Potential Benefit of Intratumoral Therapies in Lung Cancer
JNJ-1900 (NBTXR3) is a novel intratumoral radioenhancer, activated by radiation therapy, which is being investigated in phase 1 clinical research for patients with lung cancer, according to Dr. Jared Weiss, who went on to explain that the therapeutic is …